Tempus Completes Acquisition of Ambry Genetics
02/03/25, 9:36 PM
Location
Money
$375 million
Industry
biotechnology
Type
acquisition
Tempus AI, Inc. has completed its acquisition of Ambry Genetics, a recognized leader in genetic testing, with the aim to improve health by understanding the relationship between genetics and disease. The acquisition is part of Tempus' strategy of leveraging diagnostics and data to drive innovation, further strengthening its ability to deliver cutting-edge solutions to clinicians, patients, and life sciences companies.
Company Info
Location
chicago, illinois, united states
Additional Info
Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world’s largest libraries of clinical and molecular data, and an operating system to make that data accessible and useful, Tempus enables physicians to make near real-time, data-driven decisions to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data.
Related People

Unlock Verified Contacts + AI Outreach
Instantly access verified contact emails — and let Fundz AI draft a hyper-personalized message based on their role, company, and your company's offering.
Jh
Jh • Executive
Email hidden • Upgrade to unlock
Trusted by teams at Google, Oracle, HubSpot & more

Unlock Verified Contacts + AI Outreach
Instantly access verified contact emails — and let Fundz AI draft a hyper-personalized message based on their role, company, and your company's offering.
Eh
Eh • Executive
Email hidden • Upgrade to unlock
Trusted by teams at Google, Oracle, HubSpot & more